Arrowhead Gets $120m From GSK For First-In-Class NASH RNAi Candidate
Executive Summary
GSK enters the NASH race with a mid-stage candidate while Arrowhead gets to focus its R&D spending on candidates it may bring to market itself.
You may also be interested in...
RNAi Returns To Spotlight As Novo Nordisk Swoops For Dicerna
The Denmark-headquartered major is impressed with what it has seen in Dicerna in the two years since the companies teamed up and is paying an 80% premium to get hold of the US firm's RNAi technology platforms.
$1bn Deal Boosts Takeda, Arrowhead’s Liver Disease And RNAi Ambitions
Takeda's global deal for one of US RNAi specialist's lead assets follows recent promising clinical results in serious disorder with no current therapeutic options.
Novartis’s Inclisiran Unscathed As Arrowhead Falls Short
Arrowhead’s drug has failed to match inclisiran’s performance, but its RNAi platform has other promising candidates.